LobbyingInvivyd lobbying by quarter
Invivyd IVVD's latest lobbying report covers Q2 2026, at $180K. The four quarters Q4 2025–Q3 2026 total $280K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medical/Disease Research/Clinical Labs.
InvivydIVVD
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $280K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $70K | 1 |
| Q1 2023 | $0 | 1 |
| Q2 2023 | $0 | 1 |
| Q3 2023 | $0 | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $90K | 3 |
| Q2 2024 | $87K | 2 |
| Q3 2024 | $6,000 | 1 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $20K | 2 |
| Q1 2026 | $80K | 3 |
| Q2 2026 | $180K | 3 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$350K · 14 reports
- Medical research and clinical labs$35K · 5 reports
- Manufacturing$30K · 1 reports
- Budget and appropriations$29K · 2 reports
- Disaster planning and emergencies$29K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES14 reports
- SENATE14 reports
- Health & Human Services, Dept of (HHS)9 reports
- Food & Drug Administration (FDA)6 reports
- Executive Office of the President (EOP)5 reports
- Office of Science & Technology Policy (OSTP)5 reports
- Centers For Medicare and Medicaid Services (CMS)1 reports
- White House Office1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseInvivyd | $190K | 9 quarters |
| Forbes-Tate | $180K | 3 quarters |
| CGCN Group | $87K | 2 quarters |
| East End Group | $76K | 3 quarters |
| King & Spalding | $0 | 2 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| ANDREW HAWKINS | Rep. Rogers, LA, Chief of Staff | Q3 2024 |
| KELLY CHILDRESS LANGE | Rep. Shimkus, LA; Rep. Rogers, Health Policy Director | Q3 2024 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | Forbes-Tate | $120K |
| 06/24for Q2 | In-house | $60K |
| 04/28for Q2 | King & Spalding | Under $5,000 |
| 04/23for Q1 | In-house | $20K |
| 04/20for Q1 | King & Spalding | Under $5,000 |
| 04/20for Q1 | Forbes-Tate | $60K |
| 02/20for Q4 2025 | In-house | $20K |
| 02/10for Q4 2025 | In-house | Under $5,000 |
| 01/23for Q1 | King & Spalding | Under $5,000 |
| 01/18for Q4 2025 | Forbes-Tate | Under $5,000 |
| 25/12/19for Q4 2025 | Forbes-Tate | Under $5,000 |
| 24/11/07for Q3 2024 | East End Group | $6,000 |
| 24/11/07for Q3 2024 | East End Group | $6,000 |
| 24/07/18for Q2 2024 | East End Group | $35K |
| 24/07/03for Q2 2024 | CGCN Group | $52K |
| 24/05/31for Q1 2024 | In-house | $20K |
| 24/05/06for Q1 2024 | East End Group | $35K |
| 24/05/06for Q1 2024 | East End Group | Under $5,000 |
| 24/04/21for Q1 2024 | CGCN Group | $35K |
| 24/04/02for Q1 2024 | CGCN Group | Under $5,000 |